INVO Fertility, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated May 23, 2025, discloses material definitive agreements and amendments to security holder rights by INVO Fertility, Inc. (the "Company"). The filing details a strategic restructuring involving the Company's wholly-owned subsidiary, NAYA Therapeutics Inc. ("NTI"), and significant modifications to the Company's capital structure, including preferred stock exchanges and debt amendments. The reporting period covers events occurring between May 23, 2025, and May 28, 2025.
Key Financial Metrics and Capital Structure
The filing does not provide standard operating financial metrics such as revenue, net income, or operating cash flow. Instead, it focuses on capital restructuring transactions:
- NTI Debt Instrument: NTI issued a secured convertible promissory note to the Company with a principal amount of $4,803,175, carrying a 7% annual interest rate, maturing November 28, 2026.
- Company Debt Restructuring: The Company exchanged an existing debenture with a principal balance of $3,934,146 for an Amended and Restated Senior Secured Convertible Debenture with a principal sum of $4,803,175, maturing February 11, 2026.
- Preferred Stock Exchanges: The Company exchanged 801,196 shares of NTI Class A Common Stock (19.9% ownership) for 6,300 shares of NTI Series A Preferred Stock (stated value $1,000/share). Additionally, holders of Series C-1 Preferred Stock (GreenBlock and FNL) exchanged their holdings for Series C-2 Preferred Stock.
- Redemption Obligation: The Company elected to redeem all outstanding Series C-1 Preferred Stock on May 31, 2025, at a price of approximately 113.86 shares of NTI Class A Common Stock per share of Series C-1 Preferred.
Material Changes Versus Prior Period
Significant changes to the Company's capital structure and subsidiary relationships include:
- Debt Extension and Increase: The maturity of the FNL debenture was extended from December 11, 2025, to February 11, 2026. The principal amount increased from $3,934,146 to $4,803,175, with monthly redemption payments increasing from approximately $437,127 to $686,168.
- Conversion Price Adjustments: The conversion price for the Series C-2 Preferred Stock was adjusted to $1.61 per share (down from $8.2716) as of May 1, 2025. The Amended and Restated Debenture conversion price is also set at $1.61 per share.
- Dividend Terms: Series C-2 Preferred holders are now entitled to receive dividends payable in Series C-2 Preferred shares (subject to equity conditions), whereas previously dividends were payable in common stock.
- Management Change: Dr. Daniel Teper resigned as President of the Company effective May 28, 2025.
Guidance, Outlook, and Risks
The filing does not contain forward-looking financial guidance or revenue outlooks. However, it outlines specific contingencies and risks associated with the new agreements:
- Conversion Limitations: Conversions of NTI Series A Preferred Stock and the NTI Note are capped such that the Company cannot beneficially own more than 19.99% of NTI's outstanding common stock. Similarly, conversion of the Company's Amended and Restated Debenture is capped at 4.99% ownership for the holder.
- Liquidity and Redemption Triggers: The Amended and Restated Debenture requires mandatory monthly redemptions starting August 15, 2025. Additionally, if the Company raises over $3,000,000 in equity or debt financing, one-third of gross proceeds must be applied to redeem the debenture principal.
- Security Interest Termination: A Side Letter Agreement provides that the Security Interest granted to the Company on the NTI Note will automatically terminate if NTI completes a Qualified IPO or Qualified Financing, provided NTI notifies the Company.
- Default Risks: Both the NTI Note and the Amended and Restated Debenture carry default interest rates of 12% and 15% per annum, respectively, upon an event of default.
Investor Verification Checklist
- Verify the impact of the increased monthly redemption payments ($686,168) on the Company's near-term liquidity and cash flow.
- Confirm the status of the Series C-1 Preferred redemption scheduled for May 31, 2025, and the valuation of the NTI common stock used for settlement.
- Review the "Additional Investment Right" granted to FNL, allowing them to purchase up to $10,000,000 of additional Series C-2 Preferred shares, and assess potential dilution.
- Monitor the Company's ability to raise capital without triggering mandatory debt prepayments under the Amended and Restated Debenture terms.
- Assess the implications of Dr. Daniel Teper's resignation as President on the Company's operational strategy.